Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Segment Expenditure Addition To Long Lived Assets
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SegmentExpenditureAdditionToLongLivedAssets.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s gyre pharmaceuticals — segment expenditure addition to long lived assets.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — segment expenditure addition to long lived assets?
- Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — segment expenditure addition to long lived assets of $178K in Q1 2026.
- How has Gyre Therapeutics, Inc.'s gyre pharmaceuticals — segment expenditure addition to long lived assets changed year-over-year?
- Gyre Therapeutics, Inc.'s gyre pharmaceuticals — segment expenditure addition to long lived assets increased by 45.9% year-over-year, from $122K to $178K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s gyre pharmaceuticals — segment expenditure addition to long lived assets?
- Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre pharmaceuticals — segment expenditure addition to long lived assets has grown at a -62.6% compound annual growth rate (CAGR), from $8.52M to $1.19M.
- What does gyre pharmaceuticals — segment expenditure addition to long lived assets mean?
- This measures the capital investment made by the segment to acquire or improve long-term assets such as property, plant, and equipment. It reflects the segment's commitment to infrastructure growth and capacity expansion. High levels of expenditure indicate ongoing investment in the segment's future operational capabilities.